This is the current revision of this page, as edited by Entranced98 (talk | contribs) at 00:15, 5 November 2022 (+sd). The present address (URL) is a permanent link to this version.
Revision as of 00:15, 5 November 2022 by Entranced98 (talk | contribs) (+sd)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Chemical compound Pharmaceutical compound | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C27H29N3O2 |
| Molar mass | 427.548 g·mol |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (what is this?) (verify) | |
Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.
References
- Spreitzer H (November 20, 2006). "Neue Wirkstoffe - Conivaptan". Österreichische Apothekerzeitung (in German) (24/2006).
- "Conivaptan hydrochloride". Molecule of the Month. Prous Science. November 2006. Archived from the original on 2012-02-13.
| Diuretics (C03) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Sulfonamides (and etacrynic acid) |
| ||||||||
| Potassium-sparing (at CD) |
| ||||||||
| Osmotic diuretics (PT, DL) | |||||||||
| Vasopressin receptor inhibitors (DCT and CD) | |||||||||
| Other | |||||||||
| Combination products | |||||||||
| |||||||||
 | This antihypertensive-related article is a stub. You can help Misplaced Pages by expanding it. |